Skip to main content
Erschienen in: BMC Nephrology 1/2022

Open Access 01.12.2022 | Research

Prediction of chronic kidney disease after orthotopic liver transplantation: development and validation of a nomogram model

verfasst von: Dandan Guo, Huifang Wang, Jun Liu, Hang Liu, Ming Zhang, Zixuan Fu, Xuemei Liu

Erschienen in: BMC Nephrology | Ausgabe 1/2022

Abstract

Background

We aimed to develop and validate a nomogram model for predicting CKD after orthotopic liver transplantation (OLT).

Methods

The retrospective data of 399 patients who underwent transplantation and were followed in our centre were collected. They were randomly assigned to the training set (n = 293) and validation set (n = 106). Multivariable Cox regression analysis was performed in the training set to identify predictors of CKD. According to the Cox regression analysis results, a nomogram model was developed and validated. The renal function of recipients was monitored, and the long-term survival prognosis was assessed.

Results

The incidence of CKD at 5 years after OLT was 25.6%. Cox regression analysis identified several predictors of post-OLT CKD, including recipient age at surgery (HR 1.036, 95% CI 1.006-1.068; p = 0.018), female sex (HR 2.867, 95% CI 1.709-4.810; p < 0.001), preoperative hypertension (HR 1.670, 95% CI 0.962-2.898; p = 0.068), preoperative eGFR (HR 0.996, 95% CI 0.991-1.001; p = 0.143), uric acid at 3 months (HR 1.002, 95% CI 1.001-1.004; p = 0.028), haemoglobin at 3 months (HR 0.970, 95% CI 0.956-0.983; p < 0.001), and average concentration of cyclosporine A at 3 months (HR 1.002, 95% CI 1.001-1.003; p < 0.001). According to these parameters, a nomogram model for predicting CKD after OLT was constructed and validated. The C-indices were 0.75 and 0.80 in the training and validation sets. The calibration curve of the nomogram showed that the CKD probabilities predicted by the nomogram agreed with the observed probabilities at 1, 3, and 5 years after OLT (p > 0.05). Renal function declined slowly year by year, and there were significant differences between patients divided by these predictors. Kaplan-Meier survival analysis showed that the survival prognosis of recipients decreased significantly with the progression of renal function.

Conclusions

With excellent predictive abilities, the nomogram may be a simple and reliable tool to identify patients at high risk for CKD and poor long-term prognosis after OLT.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AKI
Acute kidney injury
AST
Aspartate aminotransferase
ALT
Alanine transaminase
AIC
Akaike’s information criterion
BMI
Body mass index
BUN
Blood urea nitrogen
CKD
Chronic kidney disease
CKD-MDRD
the Modification of Diet in Renal Disease equation
CysC
Cystatin
C1q
Complement C1q
CsA
Cyclosporin A
CI
Confidence interval
DBIL
Serum direct bilirubin
eGFR
Estimated glomerular filtration rate
ESRD
End-stage renal disease
FK506
Tacrolimus
Glu
Glucose
HR
Hazard ratio
IQR
Interquartile range
IRI
Ischemia reperfusion injury
IBIL
Serum indirect bilirubin
KDIGO
Kidney Disease Improving Global Outcomes
LVEF
Left ventricular ejection fraction
LDH
Lactate dehydrogenase
MAP
Mean arterial pressure
MELD
Model for End-Stage Liver Disease
NLR
Neutrophil lymphocyte ratio
N/LP
Ratio of Neutrophil to lymphocyte and platelet
OLT
Orthotopic liver transplantation
POD
Postoperative day
Peak AST
AST peak value within first 24 h after OLT
PLR
Platelet lymphocyte ratio
RRT
Renal replacement therapy
sCr
Plasma creatinine
TBIL
Serum total bilirubin
UA
Uric acid

Introduction

Chronic kidney disease (CKD) is a common and significant complication after orthotopic liver transplantation (OLT). With the progression of surgical technology, perioperative treatment, and immunosuppressants, the survival rates of patients after OLT have dramatically improved to 90 and 75% at 1 and 5 years after OLT, respectively [1]. Long-term complications, such as CKD and cardiovascular events, are receiving increasing attention from clinical specialists. The prevalence of CKD reported in the literature was 4 ~ 27.5% in 1 year [24], 15 ~ 60% in 5 years [2, 4, 5], and 25 ~ 50% in 10 years after OLT [6, 7]. CKD is a primary contributor to morbidity and mortality after OLT, including an increased risk of allograft dysfunction, cardiovascular events [8], and death [4, 9], which has elicited concern regarding post-OLT management. However, only a limited number of studies have assessed long-term renal outcomes after OLT, which has important implications for patient management.
Studies have shown that the causes of CKD after OLT are complex and may include preoperative (age, female sex, history of diabetes mellitus (DM) or hypertension, hyperlipidaemia, and hepatitis C) and postoperative (calcineurin inhibitor (CNI) toxicity, prolonged ischaemia, and haemodynamic instability) factors [6, 1013]. There have been controversial results regarding a direct association between perioperative AKI and post-OLT CKD [14, 15].
A credible and helpful predictive model to identify which patients are at high risk of developing CKD in clinical practice has not been developed, although it would be a useful tool for designing preventative measures, such as early decreased doses or withdrawal of CNIs and administration of non-nephrotoxic immunosuppressants. In this study, we aimed to develop and validate a reliable nomogram model for predicting CKD after OLT. With this model, we can identify patients at high risk for CKD early and take targeted measures to prevent or slow the development and progression of CKD.

Methods

Study population

All adult patients who underwent OLT from April 2013 to October 2020 at our centre were enrolled in our study, and their medical records were retrospectively reviewed. Recipients with a minimal follow-up time of 6 months after transplantation were included. The exclusion criteria included retransplantation, baseline estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, renal replacement therapy (RRT) before liver transplantation, multiorgan transplantation, follow-up less than 6 months, and age < 18 years. Finally, 399 patients were enrolled in our study. They were randomly allocated to the training set (n = 293) and the validation set (n = 106) (Fig. 1).
The study was conducted according to the principles of the Declaration of Helsinki and approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University (the ethics approval number is QYFY WZLL 26283).

Data collection and definitions

Demographic details, relevant preoperative and postoperative laboratory test results, and concentrations of CNIs were recorded. AKI was defined as an increase in serum creatinine (sCr) of at least 26.5 μmol/l within 48 h or more than 50% within 7 days after transplantation. Peak aspartate aminotransferase (AST) within the first 24 h after transplantation was used as a measure of ischaemia-reperfusion injury (IRI) [16]. New-onset CKD was defined as CKD that occurs after OLT and as eGFR < 60 ml/min/1.73 m2 for 3 months, regardless of the presence or absence of structural kidney damage [9]. sCr, eGFR, and CNI levels were recorded before OLT as well as 1-7 days and 1, 3, 6, and 12 months after OLT and yearly thereafter until the end of follow-up. eGFR was calculated according to the Modification of Diet in Renal Disease (MDRD) equation: eGFR = 186 × creatinine (mg/dL)− 1.154 × (age)− 0.203 × 1.212 (if black) × 0.742 (if female) [17].
According to the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, the patients’ renal function was classified as follows [18]: mildly decreased: GFR 60-89 ml/min/1.73 m2; mildly to severely decreased: GFR 30-59 ml/min/1.73 m2, severely decreased: GFR 15-29 ml/min/1.73 m2; and kidney failure: GFR < 15 ml/min/1.73 m2 [19].

Immunosuppression

The standard immunosuppressive regimen after OLT consisted of CNIs combined with mycophenolate mofetil (MMF) and corticosteroids. Most patients were treated with a triple-drug regimen of tacrolimus (FK506) or cyclosporine A (CsA), MMF, and corticosteroids. Methylprednisolone was given on the day of transplantation, followed by tapering, and then converted to methylprednisolone for oral administration, which was gradually reduced. When renal function was impaired, the introduction of CNIs was delayed. Some patients were switched to mammalian target of rapamycin (mTOR) inhibitor therapy when plasma FK506 failed to reach target levels or if CKD developed. The dose of immunosuppressant was adjusted according to blood concentration.

Statistical analysis

R version 4.0.3 (R Foundation for Statistical Computing), STATA 15.0 (StataCorp, Texas, USA), and SPSS 25.0 were used to analyse the data. The median and interquartile range (IQR) were used to describe continuous variables, and the Mann–Whitney U test was performed to compare parametric variables. Categorical variables were expressed as quantities and percentages, and comparisons were made using the chi-square test or Fisher’s exact test. A Cox proportional hazards model was implemented in the training set to identify predictors of the development of CKD after liver transplantation. Factors with p < 0.05 in the univariable Cox analysis and several factors with clinical significance in previous studies were enrolled in the multivariable Cox analysis. The final Cox regression model was chosen by using forward stepwise regression with the Akaike information criterion (AIC) as the stopping rule. The AIC value for the final model was minimized with the fewest number of variables [20]. For further analysis, a nomogram was constructed based on the results of the Cox regression analysis. Then, we validated the predictive abilities of this model by examining its discrimination and calibration in the training set and validation set. The discrimination was quantified by the C-index, and the calibration was evaluated by the calibration curve. Kaplan–Meier curve analysis with the log-rank test was performed to evaluate the survival time of patients with renal function in different categories. The “rms” package was used for the nomogram and calibration curve. The “survminer” and “survival” packages were used for Kaplan–Meier analysis. For all statistical analyses, p-values of < 0.05 were considered statistically significant.

Results

Characteristics of the population

A total of 399 patients were enrolled in our study with a median follow-up of 31.5 months (IQR 18.3-51.6 months), of whom 293 patients were allocated to the training set and 106 patients were allocated to the validation set. The median age at transplantation of all patients was 52 years (IQR 45-59 years), and the majority of recipients were males (82.9%). The main indications for OLT at our centre were hepatitis B virus (HBV)-associated hepatocellular carcinoma (49.1%), followed by HBV-associated cirrhosis (27.5%). During the first week after liver transplantation, 71.1% of the recipients developed AKI, and 36.8% developed severe AKI (stage 2-3).

Incidence of CKD after OLT

During the first week after OLT, 44.4% of recipients experienced a significant decrease in eGFR of more than 50%, including 8.3% of patients who had an eGFR of less than 30 ml/min/1.73 m2. At 1 year, 13.0% of recipients had eGFR < 60 ml/min/1.73 m2, and 0.8% had eGFR < 30 ml/min/1.73 m2. The incidences of CKD at 1, 3, and 5 years after OLT were 11.0, 20.3, and 25.6%, respectively. During the entire follow-up period, 28.6% of the recipients had renal function decreaesd, and the majority (55.1%) had eGFR mildly decreased. The mildly to severely decreased eGFR, severely decreased eGFR and end-stage renal disease (ESRD) (eGFR < 15 ml/min/1.73 m2 or long-term RRT) were observed in 26.8, 1.5, and 0.5% of the recipients, respectively. Only one recipient received a kidney transplant 19 months after OLT at our centre.

Cox regression analysis of predictors associated with the development of CKD after OLT

The incidences of CKD were 26.6 and 27.3% in the training set and validation set, respectively (p > 0.05). Except for several factors with p < 0.05, including sCr, eGFR before OLT, serum albumin (ALB), and platelet-to-lymphocyte ratio (PLR) at 3 months after OLT, there were no significant differences between the training set and validation set regarding the demographic details, relevant preoperative and postoperative laboratory test results, and concentrations of CNIs (p > 0.05) (Tables 1, 2, and 3). The factors with p < 0.05 in the univariable Cox analysis and several factors with clinical significance in previous studies were included in the multivariable Cox regression model. The multivariable Cox regression analysis identified several recipient predictors associated with post-OLT CKD, including recipient age at surgery (hazard ratio [HR] 1.036, 95% confidence interval [CI] 1.006-1.068; p = 0.018), female sex (HR 2.867, 95% CI 1.709-4.810; p < 0.001), preoperative hypertension (HR 1.670, 95% CI 0.962-2.898; p = 0.068), preoperative eGFR (HR 0.996, 95% CI 0.991-1.001; p = 0.143), uric acid (UA) at 3 months (HR 1.002, 95% CI 1.001-1.004; p = 0.028), haemoglobin (Hb) at 3 months (HR 0.970, 95% CI 0.956-0.983; p < 0.001), and average concentration of CsA at 3 months after OLT (HR 1.002, 95% CI 1.001-1.003; p < 0.001) (Table 4). Postoperative AKI was associated with the development of CKD only in the univariable Cox regression analysis. The impact of FK506 was also investigated, and its median levels at 1 and 3 months after OLT were evaluated. Interestingly, these levels were lower in patients who developed CKD (at 1 month CKD 6.6, IQR 4.9-8.5 μg/L; no CKD 8.3, IQR 6.4-10.6 μg/L; p < 0.001; at 3 months CKD 6.3, IQR 3.5-7.8 μg/L; no CKD 6.6, IQR 4.8-8.4 μg/L; p = 0.084).
Table 1
Perioperative characteristics of patients between the training set and validation set
Characteristic
Training set
(n = 293)
Validation set
(n = 106)
p-value
Demographic data
 Age (years)
52 (46-59)
51 (44-58)
0.27
 Gender (N,%)
  
0.65
  Female
52 (17.7%)
16 (15.1%)
 
  Male
241 (82.3%)
90 (84.9%)
 
 BMI (Kg/m2)
24.22 (22.32-26.40)
23.69 (21.11-26.61)
0.40
 MAP (mmHg)
92 (85-98)
91 (84-97)
0.96
 Personal history
  Smoking (N,%)
125 (42.7%)
53 (50.0%)
0.21
  Alcoholism (N,%)
140 (47.8%)
52 (49.1%)
0.82
Pathogenesis of liver disease
 HBV hepatitis (N,%)
229 (78.2%)
82 (77.4%)
0.89
 Alcoholic liver cirrhosis (N,%)
21 (7.2%)
8 (7.5%)
1.00
 Hepatocellular carcinoma (N,%)
139 (47.4%)
57 (53.8%)
0.31
 Cholestatic disease (N,%)
19 (6.5%)
4 (3.8%)
0.47
 Liver complications
  Encephalopathy (N,%)
44 (15.0%)
11 (10.4%)
0.26
  Ascites> 1 L (N,%)
25 (23.6%)
71 (24.2%)
1.00
Baseline medical status
 Diabetes mellitus (N,%)
55 (18.8%)
21 (19.8%)
0.89
 Hypertension (N,%)
38 (13.0%)
12 (11.3%)
0.73
 Coronary heart disease (N,%)
8 (2.7%)
5 (4.7%)
0.34
 Abdominal surgery history (N,%)
29 (27.4%)
62 (21.2%)
0.22
 Preoperative LVEF (%)
63 (61, 65)
62 (60, 64)
0.10
 Preoperative nonselective β receptor blockers (N,%)
24 (8.2%)
7 (6.6%)
0.68
 Preoperative diuretics (N,%)
110 (37.5%)
30 (28.3%)
0.10
Preoperative scores
 MELD score
12.94 (9.50-18.87)
12.59 (9.50-17.00)
0.31
 Child-Pugh score
10 (8-14)
9 (8-11)
0.14
Preoperative parameters
 White blood cell (×  109/L)
3.39 (2.28-4.91)
3.61 (2.26-5.33)
0.53
 Neutrophils (× 109/L)
2.28 (1.46-3.51)
2.43 (1.58-3.62)
0.57
 Lymphocyte (× 109/L)
0.67 (0.40-1.03)
0.65 (0.47, 1.11)
0.44
 Red blood cell (×  1012/L)
2.97 (2.48-3.56)
3.01 (2.56-3.66)
0.57
 Hemoglobin (g/L)
91 (76-111)
92 (78-112)
0.63
 Platelet (× 109/L)
65 (40-105)
67 (41-109)
0.94
 Total protein (g/L)
59.00 (55.00-62.93)
59.62 (54.21-64.80)
0.56
 Albumin (g/L)
35.32 (32.57-39.40)
36.20 (32.20-39.02)
0.97
 TBIL (μmol/L)
35.91 (21.70-105.80)
37.27 (20.66-77.07)
0.33
 DBIL (μmol/L)
16.00 (9.29-51.61)
14.40 (9.03-32.81)
0.40
 IBIL (μmol/L)
18.88 (11.80-52.62)
18.54 (11.10-38.70)
0.31
 ALT (U/L)
26.00 (17.00-49.00)
27.50 (18.00-53.00)
0.39
 AST (U/L)
38.00 (25.00-66.00)
36.50 (26.00-68.00)
0.76
 LDH (U/L)
159.00 (133.00-193.00)
158.00 (139.00-202.00)
0.53
 BUN (mmol/L)
4.36 (3.56-5.44)
4.22 (3.41-5.73)
0.45
 sCr (μmol/L)
60.00 (48.00-74.00)
65.00 (54.00-78.00)
0.01
 UA (μmol/L)
231.00 (179.00-293.00)
247.00 (176.00-314.00)
0.29
 eGFR (mL/min/1.73 m2)
126.44 (99.21-160.67)
111.75 (94.99, 142.60)
0.02
Postoperative parameters
 Peak AST (U/L)
1239 (636-2325)
991 (679-1774)
0.27
 Postoperative RRT (N,%)
5 (4.7%)
16 (5.5%)
1.00
 Postoperative hospital stay (day)
24 (20, 29)
25 (21, 32)
0.12
 Length of ICU stay (day)
4 (3-5)
4 (3-5)
0.59
 AKI
71 (67.0%)
213 (72.7%)
0.26
 CKD
78 (26.6%)
29 (27.4%)
0.90
Continuous variables are displayed as median and interquartile ranges
Abbreviations: BMI Body mass index, MAP Mean arterial pressure, LVEF Left ventricular ejection fraction, MELD Model for End-Stage Liver Disease, TBIL Serum total bilirubin, DBIL Serum direct bilirubin, IBIL Serum indirect bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate dehydrogenase, BUN Blood urea nitrogen, sCr Serum creatinine, UA Uric acid, eGFR Estimated glomerular filtration rate, Peak AST AST peak value within first 24 h after OLT
Table 2
Characteristics of patients at 1-month after OLT between the training set and validation set
Characteristic
Training set
(n = 293)
Validation set
(n = 106)
p-value
White blood cell (× 109/L)
5.23 (4.06-6.51)
4.55 (3.51-6.06)
0.02
Neutrophils (×  109/L)
3.40 (2.42-4.64)
2.96 (2.13-4.09)
0.02
Lymphocyte (× 109/L)
0.97 (0.63-1.39)
0.93 (0.65-1.29)
0.93
Hemoglobin (g/L)
114 (102-126)
113 (99-125)
0.70
Platelet (× 109/L)
167 (109-253)
156 (103-232)
0.41
NLR
3.33 (2.29-5.68)
3.13 (2.21-4.41)
0.12
PLR
150.99 (111.34-252.34)
165.71 (106.17-238.22)
0.78
N/LP
0.021 (0.011-0.045)
0.020 (0.012-0.034)
0.38
Total protein (g/L)
65.68 (59.52-70.14)
65.16 (60.40-70.01)
0.81
Albumin (g/L)
40.58 (38.46-43.71)
40.60 (37.49-44.08)
0.73
TBIL (μmol/L)
17.52 (14.07-28.07)
19.81 (14.88-30.00)
0.12
DBIL (μmol/L)
8.32 (5.84-13.66)
9.50 (6.50-15.50)
0.12
IBIL (μmol/L)
9.30 (7.16-13.40)
10.40 (7.71-14.74)
0.19
ALT (U/L)
28.00 (16.00-53.00)
27.00 (15.00-56.00)
0.60
AST (U/L)
19.00 (14.00-30.00)
18.00 (13.00-26.00)
0.22
LDH (U/L)
167.00 (148.00-204.00)
167.00 (141.00-205.00)
0.69
Glu (mmol/L)
5.55 (4.80-6.82)
5.38 (4.69-6.75)
0.57
CysC (mg/L)
1.17 (1.01-1.47)
1.18 (1.01-1.39)
0.66
C1q (mg/L)
165 (139-198)
171 (142-199)
0.46
BUN (mmol/L)
6.17 (4.85-7.62)
5.82 (4.74-7.51)
0.43
sCr (μmol/L)
76.5 (56.0-92.0)
72.0 (54.0, 86.0)
0.30
UA (μmol/L)
323.00 (245.00-405.00)
307.00 (239.00-374.00)
0.19
eGFR (mL/min/1.73 m2)
95.48 (78.01-134.82)
104.88 (81.69-141.05)
0.36
Average concentration of FK506
7.90 (6.00-12.40)
7.80 (5.86-10.03)
0.76
Average concentration of CsA
707.55 (242.98-1219.70)
369.95 (261.80-949.25)
0.43
Average concentration of Rapamycin
2.75 (2.72-427.35)
1.68 (1.66-3.74)
0.40
Continuous variables are displayed as median and interquartile ranges
Abbreviations: NLR Neutrophil lymphocyte ratio, PLR Platelet lymphocyte ratio, N/LP Ratio of Neutrophil to lymphocyte and platelet, TBIL Serum total bilirubin, DBIL Serum direct bilirubin, IBIL Serum indirect bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate dehydrogenase, Glu Glucose, CysC Cystatin, C1q Complement C1q, BUN Blood urea nitrogen, sCr Serum creatinine, UA Uric acid, eGFR Estimated glomerular filtration rate, FK506 Tacrolimus, CsA Cyclosporin A
Table 3
Characteristics of patients at 3-months after OLT between the training set and validation set
Characteristic
Training set
(n = 293)
Validation set
(n = 106)
p-value
Neutrophils (× 109/L)
2.49 (1.86-3.50)
2.61 (1.92-3.57)
0.43
Lymphocyte (×  109/L)
1.15 (0.88-1.54)
1.16 (0.8-1.57)
0.70
Hemoglobin (g/L)
130 (117-139)
130 (119-141)
0.64
Platelet (× 109/L)
114 (90-175)
132 (93-186)
0.11
NLR
2.17 (1.49-3.06)
2.33 (1.58-3.50)
0.22
PLR
102.99 (76.47-151.76)
120.41 (87.33-161.27)
0.04
N/LP
0.018 (0.012-0.027)
0.018 (0.01-0.029)
0.92
Albumin (g/L)
41.60 (37.41-44.70)
42.80 (39.50-45.42)
0.02
TBIL (μmol/L)
15.26 (11.33-19.49)
15.30 (11.08-21.25)
0.88
DBIL (μmol/L)
5.22 (4.14-7.40)
5.48 (3.80-7.79)
0.89
ALT (U/L)
21.00 (15.00-37.00)
22.00 (14.00-36.00)
0.95
AST (U/L)
20.00 (16.00-27.00)
20.00 (16.00-30.00)
0.34
Glu (mmol/L)
5.47 (4.79-6.28)
5.37 (4.86-6.35)
0.87
CysC (mg/L)
1.135 (0.965-1.375)
1.125 (0.985-1.325)
0.99
C1q (mg/L)
168 (139-198)
171 (145-194)
0.74
BUN (mmol/L)
5.90 (4.91-7.58)
5.97 (4.94-6.97)
0.70
sCr (μmol/L)
85.00 (66.00-93.00)
80.00 (60.00-93.00)
0.19
UA (μmol/L)
359.00 (305.00-439.00)
356.00 (292.00-416.00)
0.38
eGFR (mL/min/1.73 m2)
92.76 (80.28-131.31)
99.72 (80.29-147.29)
0.24
Average concentration of FK506
7.00 (5.40-8.50)
7.35 (5.15-8.98)
0.51
Average concentration of CsA
390.60 (246.25-575.35)
121.28 (73.68-478.19)
0.09
Average concentration of Rapamycin
4.14 (3.59-5.12)
3.97 (2.92-4.51)
0.33
Continuous variables are displayed as median and interquartile ranges
Abbreviations: NLR Neutrophil lymphocyte ratio, PLR Platelet lymphocyte ratio, N/LP Ratio of Neutrophil to lymphocyte and platelet, TBIL Serum total bilirubin, DBIL Serum direct bilirubin, IBIL Serum indirect bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDH Lactate dehydrogenase, Glu Glucose, CysC Cystatin, C1q Complement C1q, BUN Blood urea nitrogen, sCr Serum creatinine, UA Uric acid, eGFR Estimated glomerular filtration rate, FK506 Tacrolimus, CsA Cyclosporin A
Table 4
Multivariable cox regression analysis for predictors of CKD
Factors
b
HR
95% CI
P-value
Age
0.035
1.036
1.006-1.068
0.018
Female
1.029
2.867
1.709-4.810
< 0.001
Hypertension
0.479
1.670
0.962-2.898
0.068
eGFR before surgery
−0.004
0.996
0.991-1.001
0.143
Uric acid at 3 months
0.002
1.002
1.001-1.004
0.028
Hemoglobin at 3 months
−0.031
0.970
0.956-0.983
< 0.001
Average concentration of CsA3 at 3 months
0.002
1.002
1.001-1.003
< 0.001
Abbreviations: b Coefficient, HR Hazard ratio, CI Confidence interval, eGFR Estimated glomerular filtration rate, CsA Cyclosporin A

Development and validation of a nomogram model for predicting CKD after OLT

A nomogram model for predicting CKD after OLT was constructed based on the results of the multivariable Cox regression model (Fig. 2). Points were assigned to the seven identified predictors based on their regression coefficients. For an individual patient, the points of each factor can be summed to calculate the estimated probabilities of CKD at 1, 3, and 5 years after OLT. Then, the nomogram was validated in the training set and validation set. The C-indices were 0.75 (95% CI 0.72-0.78) and 0.80 (95% CI 0.75-0.85) in the training set and validation set, respectively. The calibration curve of the nomogram showed that the CKD probabilities predicted by the nomogram agreed with the observed probabilities at 1, 3, and 5 years after OLT (p > 0.05) (Fig. 3). These results indicated that the nomogram model could accurately predict the risk of CKD after OLT using the perioperative predictors mentioned above.

Renal recovery and long-term prognosis of recipients

After the first week, renal function recovered rapidly in most recipients but decreased slowly after surgery. Based on the predictors of CKD in the multivariable analysis, including recipients’ age, sex, hypertension, preoperative eGFR, uric acid, and haemoglobin at 3 months after OLT, we divided the recipients into different groups. The differences in the changes in renal function between these groups are presented in Fig. 4. eGFR dropped sharply in the first 7 days after OLT due to postoperative AKI. Subsequently, eGFR increased sharply as renal function recovered and gradually decreased year by year. Because there were only a few patients with ESRD, they were included in the severely decreased renal function group. After a median follow-up period of 31.5 months (IQR 18.3-51.6 months), the mortality rates were 2.2, 4.1, and 1.8% in the mildly, mildly to severely, and severely decreased renal function groups, respectively (p < 0.001). Kaplan-Meier survival analysis with the log-rank test showed that survival was significantly different among these three groups (log-rank =70.829, p < 0.01, Fig. 5).

Discussion

The increase in the number of long-term survivors of OLT raises questions about the increasing number of patients who develop CKD and ESRD. In our study, 25.6% of 399 recipients developed CKD at 5 years after OLT, which was consistent with that in previous reports as described earlier in this article. The survival curve showed that post-OLT CKD was a strong predictor of patient prognosis, including mortality. The time-dependent changes in renal function indicated that eGFR declined slowly year by year. It is important to identify patients at risk for CKD, especially in the early course, to slow the occurrence and progression of CKD.
Although different studies have attempted to identify the best predictors of renal dysfunction after liver transplantation, a reliable and simple model to accurately predict CKD is still lacking. For this reason, we chose to construct and validate a monogram model based on Cox regression analysis. A nomogram model can integrate multiple factors, enabling clinicians to comprehensively predict the prognosis of a patient and make clinical decisions. The model developed in our study integrated patients’ age at surgery, female sex, preoperative hypertension, baseline eGFR, UA, Hb, and average plasma concentration of CsA at 3 months after OLT as predictors of the development of CKD.
The first predictor in our model was female sex, which has previously been recognized as a risk factor for CKD. Female patients suffered a faster decline in renal function, as illustrated by the plot of the decrease in eGFR between males and females in this study. In contrast, among nontransplant patients, male sex was associated with a faster decline in eGFR. Female sex is also a risk factor for CKD after heart, lung, and kidney transplantation. The exact mechanism of this association is not clear. A possible explanation may be that females may be more susceptible to CNI-mediated renal injury [21].
Recipients with hypertension and low eGFR are more prone to suffering IRI during and after surgery due to trauma and circulation instability [6]. Although their p values were > 0.05, our nomogram model showed that preoperative hypertension and low eGFR were important predictors of new-onset CKD after OLT.
In our population study, the UA level at 3 months after OLT was found to be a risk factor for new-onset CKD. Elevated serum levels of UA are associated with the onset and progression of CKD in many populations, such as the general population [22], patients with hypertension [23], and kidney transplantation patients [24]. Although hyperuricaemia is common after OLT, its association with the development of CKD has not been well described. It was reported that post-OLT hyperuricaemia was related to immunosuppressants, primarily CNIs (CsA and FK506), which decrease UA excretion by reducing GFR and increasing UA reabsorption in renal tubules. The incidence of hyperuricaemia was much higher in recipients treated with CsA than in those treated with FK506 in some reports. Multiple mechanisms are related to renal damage caused by UA, including contributions to the development of hypertension [25], activation of the renin-angiotensin-aldosterone system (RAAS) [2628], inflammation, and oxidative stress reactions [29]. In patients with CKD, a high level of serum UA was associated with cardiovascular diseases [30], a higher risk of incident RRT, and all-cause mortality [31]. It is important to reduce UA levels in OLT recipients to prevent the occurrence of CKD and improve prognosis. The treatments include changing the unhealthy lifestyle of patients and using drugs such as febuxostat, allopurinol, and topiroxostat. In addition, CNIs should be avoided, or the dose should be reduced as much as possible. Some reports have shown that the reduction or even withdrawal of CNIs after OLT combined with MMF or mTOR inhibitors can contribute to the reduction in UA levels [32, 33]. Therefore, serum UA levels should be closely monitored by clinicians during follow-up. Immunosuppression programs should be individualized according to the specific situation of the recipient. Due to its negative impact on prognosis, serum levels of uric acid were monitored and intervened carefully for all patients in our centre. The HR of UA at 3 months was low in this study, which might be related to the intervention of lowering UA during follow-up.
Another risk factor for CKD after OLT was low Hb levels at 3 months. The association between preoperative Hb and CKD after OLT was found in a previous Chinese cohort study [6]. In our study, low Hb at 3 months after OLT may contribute to CKD by reducing the oxygen capacity of the blood, enhancing oxidative stress, and impairing haemostasis. In addition, a recent study from Korea revealed that CKD patients with anaemia are at high risk for hyperuricaemia, which may further promote the development of CKD. The reason for the decrease in Hb at 3 months may be related to the use of immunosuppressive medications. MMF, azathioprine, and sirolimus are common causes of bone marrow suppression, which thus leads to a decrease in Hb after OLT [34].
It is well known that the dose-dependent nephrotoxicity of CNIs also plays an important role in the occurrence of new-onset CKD. In our study, the average plasma concentration of CsA at 3 months was an independent risk factor for the development of post-OLT CKD. Calcineurin stimulates vascular endothelial cells to secrete endothelin, release angiotensin II and overexpress transforming growth factor-β. This process is accompanied by a decrease in stromal degrading enzyme activity, leading to the hyperconstruction of glomerular arterioles, hyalinosis, chronic thromboembolism, and the excessive synthesis of extracellular matrix. Finally, it results in tubule atrophy and interstitial fibrosis and reduces renal blood flow and glomerular filtration [6]. However, the concentration of tacrolimus was not included in the nomogram model. Most of our recipients were on long-term immunosuppression with tacrolimus, and interestingly, CKD recipients had significantly lower levels of tacrolimus. This finding was consistent with the finding of some previous studies, which did not show a correlation between tacrolimus levels and the development of CKD [35]. This may be due to the adjustment of tacrolimus dose in patients with known renal impairment in our centre.
Finally, a nomogram model was constructed based on multivariable Cox regression analysis, which provides clinicians with a visual tool to understand the impact of predictors on renal function after OLT. In addition, by comprehensively analysing all predictors included, we can accurately calculate the probabilities of CKD for each recipient, making the results more personalized. After evaluation, the C-index of the nomogram model was 0.75 for the training set and 0.80 for the validation set, indicating that the nomogram model has a strong ability to distinguish patients with and without CKD. The calibration curves in the training set and validation set showed that the predicted probabilities of CKD at 1, 3, and 5 years after OLT were consistent with the observed probabilities, which indicates the accurate prediction ability of our model.
Several prediction models for CKD after OLT have been developed. A CKD prediction formula was developed from New York based on urinary neutrophil gelatinase-associated lipocalin (uNGAL) at 24 h after OLT as the most important risk factor. However, uNGAL-24 h is not routinely examined in other centres. Moreover, this prediction model has not been validated in terms of its calibration abilities [36]. Recently, a biomarker model predictive of renal outcomes after liver transplantation was constructed based on a large population from multiple centres. The levels of β2-microglobulin and CD40 antigen included in the prediction model are not routinely examined in other centres. Despite the high area under the curve (AUC), no calibration verification was performed [37]. The pocket guide to identifying patients at risk for CKD after liver transplantation, which includes hepatitis C virus (HCV) as one of the predictive factors, is a reliable prediction model for German patients. However, it does not apply to Chinese patients because HCV is more common in Western countries than in China [38]. Another model from Italy has been validated through AUC calculation and calibration; however, the sample size was relatively small, and there was no visual tool developed for the model [2]. In addition, none of these prediction models have been used in Chinese recipients.
Compared with these models, our model has the following advantages. First, it is the first nomogram model constructed based on OLT recipients for predicting CKD. Second, the predictors included in our model were readily available at surgery or routinely tested in follow-up, which is conducive to the popularization of the model. Third, our model had excellent discrimination and calibration abilities in the training set and validation set. It is a simple and reliable tool to distinguish recipients at high risk for CKD after OLT at 1, 3, and 5 years. In addition, this model can be used earlier at 3 months after OLT, assisting clinicians in adjusting immunosuppressive drugs in advance.
This study had several limitations. First, this study had a retrospective single-centre design, and the sample size was small, so the model should be evaluated prospectively in other large multi-centre studies to demonstrate its applicability. Second, the use of MDRD to assess renal function may lack accuracy in candidates awaiting liver transplantation, possibly because of reduced muscle mass and/or hyperbilirubinemia. It would overestimate renal function in patients with poor function (GFR < 40 mL/min) and underestimate renal function in patients with reasonable renal function (GFR > 40 mL/min) [17]. However, this is the most frequently used method to estimate kidney function. Third, due to data deficiency, we did not analyse the relationship between urinalysis data such as proteinuria and postoperative CKD. Fourth, to more accurately clarify the impact of CKD on the long-term prognosis after OLT, it is necessary to conduct a longer follow-up study.
In conclusion, the renal function of most recipients decreased and recovered rapidly in the first week after OLT and then decreased slowly year by year. Patients with severe CKD had a poor survival prognosis. We constructed a nomogram model for predicting post-OLT CKD for the first time. With excellent discrimination and calibration, this nomogram model can accurately predict patients at high risk for CKD after OLT. Therefore, we can take measures to prevent or slow the development and progression of CKD in advance, such as reducing UA levels, improving Hb levels, and withdrawing or minimizing the use of CNIs in follow-up.

Acknowledgments

Not applicable.

Declarations

The study was conducted according to the principles of the Declaration of Helsinki and approved by the Medical Ethics Committee of The Affiliated Hospital of Qingdao University with informed consent of all subjects and/or their legal guardian(s) (the ethics approval number is QYFY WZLL 26283). All methods were performed in accordance with the relevant guidelines and regulations.
Not applicable.

Competing interests

The authors report no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(Suppl 1):69–96.CrossRef Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(Suppl 1):69–96.CrossRef
2.
Zurück zum Zitat Giusto M, Berenguer M, Merkel C, et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation. 2013;95:1148–53.CrossRef Giusto M, Berenguer M, Merkel C, et al. Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation. 2013;95:1148–53.CrossRef
3.
Zurück zum Zitat Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012;18:1290–301.CrossRef Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012;18:1290–301.CrossRef
4.
Zurück zum Zitat Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol. 2014;20:11356–62.CrossRef Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol. 2014;20:11356–62.CrossRef
5.
Zurück zum Zitat Maurel P, Prémaud A, Carrier P, et al. Evaluation of longitudinal exposure to tacrolimus as a risk factor of chronic kidney disease occurrence within the first year post-liver transplantation. Transplantation. 2020;105:1585–94.CrossRef Maurel P, Prémaud A, Carrier P, et al. Evaluation of longitudinal exposure to tacrolimus as a risk factor of chronic kidney disease occurrence within the first year post-liver transplantation. Transplantation. 2020;105:1585–94.CrossRef
6.
Zurück zum Zitat Li Y, Li B, Wang W, et al. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant. Exp Ther Med. 2018;15:3589–95.PubMedPubMedCentral Li Y, Li B, Wang W, et al. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant. Exp Ther Med. 2018;15:3589–95.PubMedPubMedCentral
7.
Zurück zum Zitat Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation. 2011;92:1358–63.CrossRef Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation. 2011;92:1358–63.CrossRef
8.
Zurück zum Zitat Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–4.CrossRef Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–4.CrossRef
9.
Zurück zum Zitat Peng JC, Li YJ, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24:806–12.CrossRef Peng JC, Li YJ, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24:806–12.CrossRef
10.
Zurück zum Zitat Lamattina JC, Foley DP, Mezrich JD, et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol. 2011;6:1851–7.CrossRef Lamattina JC, Foley DP, Mezrich JD, et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol. 2011;6:1851–7.CrossRef
11.
Zurück zum Zitat Bahirwani R, Forde KA, Mu Y, et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transpl. 2014;28:205–10.CrossRef Bahirwani R, Forde KA, Mu Y, et al. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transpl. 2014;28:205–10.CrossRef
12.
Zurück zum Zitat Kang GW, Lee IH, Ahn KS, et al. One-year follow-up of the changes in renal function after liver transplantation in patients without chronic kidney disease. Transplant Proc. 2016;48:1190–3.CrossRef Kang GW, Lee IH, Ahn KS, et al. One-year follow-up of the changes in renal function after liver transplantation in patients without chronic kidney disease. Transplant Proc. 2016;48:1190–3.CrossRef
13.
Zurück zum Zitat Campo A. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563–5.CrossRef Campo A. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563–5.CrossRef
14.
Zurück zum Zitat Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114:919–26.CrossRef Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114:919–26.CrossRef
15.
Zurück zum Zitat Leithead JA, Ferguson JW, Bates CM, et al. Chronic kidney disease after liver transplantation for acute liver failure is not associated with perioperative renal dysfunction. Am J Transplant. 2011;11:1905–15.CrossRef Leithead JA, Ferguson JW, Bates CM, et al. Chronic kidney disease after liver transplantation for acute liver failure is not associated with perioperative renal dysfunction. Am J Transplant. 2011;11:1905–15.CrossRef
16.
Zurück zum Zitat Rahman S, Davidson BR, Mallett SV. Early acute kidney injury after liver transplantation: predisposing factors and clinical implications. World J Hepatol. 2017;9(18):823–32.CrossRef Rahman S, Davidson BR, Mallett SV. Early acute kidney injury after liver transplantation: predisposing factors and clinical implications. World J Hepatol. 2017;9(18):823–32.CrossRef
17.
Zurück zum Zitat Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9.CrossRef Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9.CrossRef
18.
Zurück zum Zitat National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1). National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1).
19.
Zurück zum Zitat KDIGO AKI Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. KDIGO AKI Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
20.
Zurück zum Zitat Yap W-K, Shih M-C, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1:e183242.CrossRef Yap W-K, Shih M-C, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1:e183242.CrossRef
21.
Zurück zum Zitat Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are associated with the late decline in renal function following liver transplantation. Clin Transpl. 2012;26:E316–23.CrossRef Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are associated with the late decline in renal function following liver transplantation. Clin Transpl. 2012;26:E316–23.CrossRef
22.
Zurück zum Zitat Tada K, Maeda T, Takahashi K, et al. Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease. Clin Exp Nephrol. 2021;25:751–9.CrossRef Tada K, Maeda T, Takahashi K, et al. Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease. Clin Exp Nephrol. 2021;25:751–9.CrossRef
23.
Zurück zum Zitat Kaewput W, Thongprayoon C, Rangsin R, et al. Association between serum uric acid and chronic kidney disease in patients with hypertension: a multicenter nationwide cross-sectional study. J Evid Based Med. 2019;12:235–42.CrossRef Kaewput W, Thongprayoon C, Rangsin R, et al. Association between serum uric acid and chronic kidney disease in patients with hypertension: a multicenter nationwide cross-sectional study. J Evid Based Med. 2019;12:235–42.CrossRef
24.
Zurück zum Zitat Yang H, Chen Q, Huang A, et al. The impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292–307.CrossRef Yang H, Chen Q, Huang A, et al. The impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292–307.CrossRef
25.
Zurück zum Zitat Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896–902.CrossRef Feig DI, Madero M, Jalal DI, et al. Uric acid and the origins of hypertension. J Pediatr. 2013;162:896–902.CrossRef
26.
Zurück zum Zitat Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRef Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRef
27.
Zurück zum Zitat Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity. Hypertension. 2017;69(2):339–48.CrossRef Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity. Hypertension. 2017;69(2):339–48.CrossRef
28.
Zurück zum Zitat Eräranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008;26(8):1661–8.CrossRef Eräranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008;26(8):1661–8.CrossRef
29.
Zurück zum Zitat Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890–6. Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890–6.
30.
Zurück zum Zitat Chiu T-H, Wu P-Y, Huang J-C, et al. Hyperuricemia is associated with left ventricular dysfunction and inappropriate left ventricular mass in chronic kidney disease. Diagnostics. 2020;10:514.CrossRef Chiu T-H, Wu P-Y, Huang J-C, et al. Hyperuricemia is associated with left ventricular dysfunction and inappropriate left ventricular mass in chronic kidney disease. Diagnostics. 2020;10:514.CrossRef
31.
Zurück zum Zitat Lee C-L, Wang J-S. Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo medical journal =. Rev Paul Med. 2019;137:523–9. Lee C-L, Wang J-S. Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo medical journal =. Rev Paul Med. 2019;137:523–9.
32.
Zurück zum Zitat Pons JA, Ramírez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transpl. 2009;23:329–36.CrossRef Pons JA, Ramírez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transpl. 2009;23:329–36.CrossRef
33.
Zurück zum Zitat Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012;44:2369–72.CrossRef Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012;44:2369–72.CrossRef
34.
Zurück zum Zitat Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 2004;10(2):165–73.CrossRef Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 2004;10(2):165–73.CrossRef
35.
Zurück zum Zitat Kalisvaart M, Schlegel A, Trivedi PJ, et al. Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 2019;25:922–33.CrossRef Kalisvaart M, Schlegel A, Trivedi PJ, et al. Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 2019;25:922–33.CrossRef
36.
Zurück zum Zitat Cullaro G, Pisa JF, Brown RS, et al. Early postoperative neutrophil gelatinase-associated lipocalin predicts the development of chronic kidney disease after liver transplantation. Transplantation. 2018;102:809–15.CrossRef Cullaro G, Pisa JF, Brown RS, et al. Early postoperative neutrophil gelatinase-associated lipocalin predicts the development of chronic kidney disease after liver transplantation. Transplantation. 2018;102:809–15.CrossRef
37.
Zurück zum Zitat Levitsky J, Asrani SK, Klintmalm G, et al. Discovery and validation of a biomarker model (PRESERVE) predictive of renal outcomes after liver transplantation. Hepatology. 2020;71:1775–86.CrossRef Levitsky J, Asrani SK, Klintmalm G, et al. Discovery and validation of a biomarker model (PRESERVE) predictive of renal outcomes after liver transplantation. Hepatology. 2020;71:1775–86.CrossRef
38.
Zurück zum Zitat Weismüller TJ, Lerch C, Evangelidou E, et al. A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int. 2015;28:519–28.CrossRef Weismüller TJ, Lerch C, Evangelidou E, et al. A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int. 2015;28:519–28.CrossRef
Metadaten
Titel
Prediction of chronic kidney disease after orthotopic liver transplantation: development and validation of a nomogram model
verfasst von
Dandan Guo
Huifang Wang
Jun Liu
Hang Liu
Ming Zhang
Zixuan Fu
Xuemei Liu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2022
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02650-1

Weitere Artikel der Ausgabe 1/2022

BMC Nephrology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.